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a b s t r a c t
The ability to compare incremental changes in Quality Adjusted Life Years (QALYs) generated by different
condition-speciﬁc preference-based measures (CSPBMs), or indeed between generic measures, is often
criticised even where the valuation methods and source of values are the same. A key concern is the
impact of excluding key dimensions from a descriptive system. This study examines the impact of adding
a generic pain/discomfort dimension to a CSPBM, the AQL-5D (an asthma-speciﬁc CSPBM), by valuing
samples of states from the AQL-5D with and without the new dimension using an interviewer admin-
istered time trade-off with a sample of the UK general public. 180 respondents provided 720 valuations
for states with and without pain/discomfort. As expected the additional pain/discomfort dimension was
found to have a signiﬁcant and relatively large coefﬁcient. More importantly for comparing changes in
QALYs across populations the addition of pain/discomfort signiﬁcantly impacts on the coefﬁcients of the
other dimensions and the degree of impact differs by dimension and severity level. The net effect on the
utility value depends on the severity of their state: the addition of pain/discomfort at level 1 (no pain/
discomfort) or 2 (moderate pain/discomfort) signiﬁcantly increased the mean health state values in an
asthma patient population; whereas level 3 pain/discomfort (extreme) reduced values. Comparability
between measures requires that the impact of different dimensions on preferences is additive, whether
or not they are included in the classiﬁcation system. Our results cast doubt on this assumption, implying
that the chosen measure must contain all important and relevant dimensions in its classiﬁcation system.
 2011 Published by Elsevier Ltd.
Introduction
Recent years has seen the rise of generic preference-based
measures in populating cost per QALY analyses, with the EQ-5D
gaining a special status as the preferred measure for economic
evaluations submitted to the National Institute for Health and
Clinical Excellence of England and Wales (NICE, 2008). It has been
claimed that ‘generic’ preference-based measures are applicable to
all interventions and patient groups. This claim has support in
many conditions where it has been shown to be reliable, valid and
responsive (Brazier, Ratcliffe, Tsuchiya, & Solomon, 2007). However,
one or more of the generic preference-based measures have been
shown to perform poorly in some conditions, such as visual
impairment in macular degeneration (Espallargues et al, 2005),
hearing loss (Barton, Bankart, & Davis, 2004), leg ulcers (Walters,
Morrell, & Dixon, 1999), and urinary incontinence (Haywood,
Garratt, Lall, Smith, & Lamb, 2008). For this and other reasons
many clinicians and researchers use condition-speciﬁc measures
that are not preference-based.
There has been increasing interest in the development of
condition-speciﬁc preference-based measures (CSPBM). This has
been achieved either by the development of entirely newmeasures
(e.g. Revicki, Leidy, Brennan-Diemer, Sorenson, & Togias, 1998;
Revicki, Leidy, Brennan-Diemer, Thomson, & Togias, 1998; Torrance
et al., 2004), or by developing health state classiﬁcations amenable
to valuation from existing condition-speciﬁc measures (Brazier
et al., 2008; Kok, McDonnell, & et al, 2002; Ratcliffe, Brazier,
Tsuchiya, & et al, 2009; Stevens, Brazier, McKenna, Doward, &
Cork, 2005; Young, Yang, Brazier, Tsuchiya, & Coyne, 2009).
However, there remain some fundamental concerns as to whether
they can be used to make comparisons between interventions for
different conditions (Brazier & Tsuchiya, 2010; Dowie, 2002; Gold,
Siegel, Russell, & Weinstein, 1996). Even using generic systems
does not ensure comparability, since signiﬁcant differences have
been shown between the different generic preference-based
measures (Moock & Kohlmann, 2008). One way to achieve cross
programme comparability is to use the same generic preference-
based measure. Using one instrument in all studies ensures that
different patient groups are being judged in terms of the same
dimensions of health, using the same valuation methods and utility
values obtained from the same sample. For this reason, NICE has
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expressed a preference for the EQ-5D in its reference case methods
(NICE, 2008), though other agencies interested in seeing cost utility
analysis of health care interventions have been less prescriptive.
An alternative view is that comparability can be achieved by the
use of a common numeraire like money or a year in full health.
Provided the values are obtained using the same tightly speciﬁed
valuation ‘protocol’ in terms of the valuation technique (and
variant), procedures, common anchors (full health and death),
visual aids and the same type of respondents (such as a represen-
tative sample of the general population), then a common
measuring stick is being used and so comparisons can be made
between quality adjustment weights estimated using different
descriptive systems. This means that there is no need to have
a common descriptive system.
However, there are a number of obstacles to achieving compa-
rability from using different descriptive systems including the need
to handle side-effects and co-morbidities (Brazier & Tsuchiya, 2010).
The failure to pick-up important side-effects of treatment is the
rationale in clinical research for using a generic measure alongside
a condition-speciﬁc measure in a trial. The problem for economic
evaluation is that it needs a single measure of effectiveness. Even
assuming there are no side-effects, the achievement of compara-
bility between speciﬁc preference-based instruments requires an
additional assumption, namely that the impact of different dimen-
sions on preferences is additive, whether or not they are included in
the descriptive system. The impact of breathlessness on health state
values, for example,must be the samewhetheror not thepatient has
co-morbidities that impact on dimensions not covered by the
descriptive system, such as pain in joints.
The impact of dimensions external to the descriptive system
may be the product of a form of focussing effect (or focussing
illusion). We focus on those things that are placed in front of us.
Respondents, therefore, will tend to focus on the problems
described in the health state they are valuing. This results in
respondents exaggerating the importance of the problems in the
health state they are being asked to value to the neglect of any
domains not covered by the health state classiﬁcation system. They
may have a view about the level of other dimensions, but this may
carry less weight. Or alternatively, different people may bring
different assumptions about the level of the unmentioned dimen-
sions. Either way, the addition of dimensions may have implica-
tions for the entire structure of the utility function for health.
This issue has implications for the development of add-on
dimensions to extend the coverage of generic measures like the
EQ-5D. Studies have examined the impact of adding-on dimensions
for cognition (Krabbe, Marlies, Stouthard, & et al, 1999) and sleep
(Yang et al, 2008), which in the case of the former was found to be
signiﬁcant in a student population and in the latter not signiﬁcant
in a sample of the general population using time trade-off (TTO).
The same approach can be applied to improving CSPBM that are
narrower in their focus by adding-on more generic dimensions.
This paper examines the impact of adding-on a pain/discomfort
dimension to a preference-based asthma-speciﬁc measure. Pain/
discomfort has been shown to have a large impact on health state
values across the generics, so it provides a good opportunity to test
the concerns with CSPBM raised above as well as the more general
problems associated with the add-on approach.
The main aim of this study is to examine the impact of adding
a generic pain/discomfort dimension to a CSPBM for asthma and
speciﬁcally to test whether the impact on health state values is
additive. This is achieved by asking a general population sample to
value a selection of health states deﬁned by AQL-5D (an asthma-
speciﬁc health state classiﬁcation) or AQL-6D (AQL-5D plus pain/
discomfort dimension) using TTO. Coefﬁcients for the 5 and 6
dimensional classiﬁcations are estimated and the coefﬁcients of the
common dimensions are compared. The impact on health state
values of using AQL-5D or AQL-6D is examined using data from
a randomised controlled trial.
Methods
Measures of health-related quality of life: AQL-5D and AQL-6D
The study uses the AQL-5D, which is a 5-dimension 5-level
preference-based measure for asthma (Yang et al, 2011; Young
et al, 2011). The health state classiﬁcation system was derived
from the Asthma Quality of Life Questionnaire (AQLQ) (Juniper,
Guyatt, Ferrie, & Grifﬁth, 1993, 1999) using Rasch and conven-
tional psychometric analysis (Young et al, 2011). The 5 dimensions
are: concern about asthma, shortness of breath, weather and
pollution stimuli, sleep impact and activity limitations. In the
classiﬁcation system each dimension has 5 levels of severity with
level 1 denoting no problems and level 5 indicating extreme
problems. All patient data with complete AQLQ information can be
mapped onto the AQL-5D. The original valuation study selected 99
health states for valuation using a balanced design. States were
then valued using theMeasurement and Valuation of Health (MVH)
study version of TTO, which includes a visual prop (Dolan, 1997;
Gudex, 1994). The preference weights for all states deﬁned by the
classiﬁcation model were estimated using a consistent main effects
model estimated on mean health state values (Yang et al, 2011).
In the study reported in this paper, a reduced AQL-5D health
state classiﬁcation system is valued where each dimension has 3
levels of severity: level 1 denoting no problems, level 2 denoting
some problems and level 3 denoting extreme problems (see
Table 1). These relate to levels 1, 3 and 5 in the original classiﬁcation
system. The reduced classiﬁcationwas chosen primarily to limit the
size of the valuation survey required to address the study aim. The
selection of the 3 levels also makes sense because in the original
valuation study level 2 was insigniﬁcant for all dimensions in the
regression models estimating the preference weights for the clas-
siﬁcation system. Level 4 was signiﬁcant for all dimensions but
there were inconsistencies between levels 4 and 5 for 2 dimensions
Table 1
AQL-5D and AQL-6D classiﬁcation system (3 level version).
Dimensions common to both measures
Concern about asthma
Feel concerned about having asthma none of the time
Feel concerned about having asthma some of the time
Feel concerned about having asthma all of the time
Shortness of breath
Feel short of breath as a result of asthma none of the time
Feel short of breath as a result of asthma some of the time
Feel short of breath as a result of asthma all of the time
Weather and pollution
Experience asthma symptoms as a result of air pollution none of the time
Experience asthma symptoms as a result of air pollution some of the time
Experience asthma symptoms as a result of air pollution all of the time
Sleep
Asthma interferes with getting a good night’s sleep none of the time
Asthma interferes with getting a good night’s sleep some of the time
Asthma interferes with getting a good night’s sleep all of the time
Activities
Overall, not at all limited in any activity done due to asthma
Overall, moderate or some limitation in every activity done due to asthma
Overall, totally limited in every activity done due to asthma
Pain and discomfort (Sixth dimension included in AQL-6D only)
Have no pain or discomfort
Have moderate pain or discomfort
Have extreme pain or discomfort
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(shortness of breath and activity limitations) and for all dimensions
the difference in coefﬁcients between levels 4 and 5 was small.
The AQL-6D is a classiﬁcation system consisting of the 5
dimensions of the reduced AQL-5D plus the pain/discomfort
dimension from the EQ-5D added at the end, which also has 3
levels (Brooks, 1996 (see Table 1). This extra dimension was chosen
to ensure little overlap and correlation with the existing dimen-
sions whilst ensuring the additional dimension was able to capture
potential co-morbidities and/or side-effects. One advantage of
using a dimension from an existing measure is the availability of
patient data including bothmeasures (viz. AQLQ and EQ-5D), which
enables us to test the impact of adding an additional dimension on
health state values using a patient data set from a clinical trial.
Valuation survey
This study needs to be able to capture the impact on health state
values of adding an additional dimension to the AQL-5D classiﬁ-
cation system, whilst removing the possibility that the observed
impact is due to some other factor. Comparing health state values
for AQL-6D with the AQL-5D values from the original study (Yang
et al, 2011) is unsuitable as any observed differences could be
caused by multiple factors, including different samples, different
interviewers, the reduction in the number of levels and different
techniques used to sample states for the valuation study. Therefore
in order tominimise variation for any other reason both the AQL-5D
and the AQL-6D were valued by two samples in the same valuation
survey.
Selection of states
Health states for each measure were selected using an orthog-
onal array in SPSS version 15. Sixteen health states were selected
for AQL-5D, one of which was a repeated state (11111). Eighteen
health states were selected for AQL-6D with no repeats. The worst
state for each measure (33333 and 333333) was added, taking the
number of unique health states to 16 for AQL-5D and 19 for AQL-6D.
These included 4 health states that were ‘matched’ across the two
descriptive systems in terms of the level of the non-pain dimen-
sions: states 11111 and 1111111; 12132 and 121323; 23131 and
231311; 33333 and 333333. The digits indicate the level in each
dimension, so the AQL-5D state 12132 is at level 1 in concern, level
2 in shortness of breath, level 1 in weather and pollution, level 3 in
sleep and level 2 in activities. There is no mention of pain/
discomfort. The paired AQL-6D state is the same across these
asthma-speciﬁc dimensions, but there is an explicit reference to
pain at the end that in this case is at level 3.
Health states were divided into 3 ‘card blocs’ of 8 states for each
measuremaking 6 blocks or combinations of states in all. The worst
state appeared in all card blocks and the remaining matched health
states appeared in 2 card blocs to improve power. Other states
repeated across more than one bloc for AQL-5D and AQL-6D were
chosen to reﬂect a range of severity (using summed levels and
dimensions) and levels for each dimension. Combinations of states
within card blocs were chosen to reﬂect a range of severity (using
summed levels and dimensions) and to ensure each card bloc
included each level of each dimension. During the interviews, the
health state cards were shufﬂed at the start of the rank and TTO
tasks.
Interviewers were instructed to ensure each card bloc was
valued equal times per geographical location and to work through
the blocs in order with each interviewer starting from a different
card bloc. Interviewers were asked to work through the card blocs
in order 1 to 6: 1e3 were 5D and 4e6 were 6D. Different inter-
viewers were asked to start with a different bloc ﬁrst and all blocs
were used 3e4 times per geographical area.
Respondents
Members of the general population valued 8 health states from
either AQL-5D or AQL-6D using time trade-off (TTO). The sampling
for all households to be contacted in the study was undertaken
using the AFD Names and Numbers version 3.1.25 database for
South Yorkshire (AFD Software Limited, Ramsey, UK). This sample
was balanced to the UK population according to geodemographic
proﬁles.
Interview
All households in the sample were mailed the same information
sheet and cover letter, each informing respondents that the inter-
view was concerned with understanding ‘what people think about
the way asthma impacts on people’s lives’. Respondents were
interviewed in their own home by trained interviewers who have
previous experience working on valuation studies including the
HUI2 (McCabe, Stevens, Roberts, & Brazier, 2005) and OAB-5D
(Yang, Brazier, Tsuchiya, & Coyne, 2009). The interview began
with respondents reading and self-completing both the EQ-5D and
the AQL-5D, to familiarise themselves with each classiﬁcation
system. Respondents then undertook a warm-up rank task ranking
8 health states either in AQL-5D or in AQL-6D alongside 2 generic
states ‘full health’ and ‘dead’. Respondents then completed a prac-
tise TTO question for a separate state followed by TTO questions
valuing all 8 health states seen in the rank task. The protocol uses
the York Measurement and Valuation of Health study version of
TTO (Gudex,1994) including the visual propwith generic full health
(not instrument speciﬁc full health). At the end of the interview,
respondents were asked to complete questions covering their
demographic and socio-economic characteristics. All interviews
were conducted from October 2009 to January 2010.
Analyses of preference data
TTO values were obtained using the conventional trans-
formations for states better and worse than dead to ensure
a potential range 1.0 to 1.0 (Dolan, 1997). Three exclusion criteria
were applied to the data to remove those respondents that do not
appear to understand the task. Rrespondents were excluded from
the analyses for valuing all states as identical, except in cases where
all states are valued at one. Valuing all states as equal to one may
not reﬂect a lack of understanding, but rather an unwillingness to
trade life years for better health states. A second exclusion criterion
was where respondents valued the worst possible health state
higher than every other state. Finally respondents were excluded
who valued all states as worse than dead.
The impact of adding pain/discomfort to AQL-5D was examined
in three ways. Firstly, the mean values for the matched states were
compared. Secondly, TTO values were modelled and the 5 asthma-
speciﬁc coefﬁcients were compared across AQL-5D and AQL-6D.
Thirdly, the signiﬁcance of the pain coefﬁcients in the AQL-6D
model was examined.
Comparisons of health state values
Mean health state values of the 4matched health state pairs (e.g.
33333 and 333333) were compared using independent samples
t-tests.
Modelling
Regression analysis is used to estimate the disutility associated
with each level of each dimension, in order to enable utility scores
to be estimated for all health states described by the classiﬁcation
system. Models have been estimated for the AQL-5D and the AQL-
6D using ordinary least squares and a random effects component to
allow for repeated health state values from the same respondent.
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Given the limitations of the study design and sample size it was
only possible to estimate additive models. The standard random
effects speciﬁcation is (Brazier, Roberts, & Deverill, 2002):

1 yij

¼ aþ bxiDdzj þ eij (1)
where i ¼ 1,2,.,n represents health states and j ¼ 1,2,.,m repre-
sents respondents. The dependent variable 1 yij is TTO disvalue,
where yij is the TTO value for health state i valued by respondent j,
xi is a vector of dummy explanatory variables for each level l of
dimension d of the health state classiﬁcation where level l ¼ 1 acts
as a baseline for each dimension, and zj is a vector of socio-
demographic characteristics. eij is the error term, subdivided into
eij ¼ uj þ eij, where uj is the individual random effect and eij is the
usual random error term. This speciﬁcation assumes a simple
additive functional form. The data set is not designed to formally
examine interactions within the AQL-5D, however we did exam-
ined an ‘N30 dummy variable to pick-up possible interactions
between the worst levels across the dimensions. It assumes a value
of one when any dimension is at the worst level
TTO data is notoriously non-normal and associated with being
skewed, censored at 1 and having more than one mode. The left
skew in this data, whereby 25% of the values lie between 0.9 and 1,
can be accounted for in a Tobit model with upper censoring, which
treats the data as if they arise from a censored observation mech-
anism through which observations with true values greater than
one are observed as 1.
Model performancewas assessed in terms of adjusted R squared
(where available), the likelihood ratio and the size and signiﬁcance
of individual parameter estimates. Predictive ability was assessed
by the individual level root mean square error (RMSE) and the
mean absolute error at the state level (i.e. the difference between
predicted and actual mean values at the state level). Plots were
used to illustrate possible patterns of predicted errors. The only
difference between the AQL-5D and AQL-6D models is the addition
of an extra pain/discomfort dimension. The coefﬁcients on the non-
pain dimensions of the models were compared using the z-score
test for each dimension, where an absolute z-score of 1.96 or more
would indicate a signiﬁcant difference at the 5% level.
Application of the valuation results to clinical trial data
To understand the practical implications of the ﬁndings of this
study the regression models for the AQL-5D and AQL-6D were
applied to clinical trial data. If the impact of an additional pain/
discomfort dimension is entirely independent and additive, then
health state scores of real asthma patients using AQL-6D will either
be equal to or worse than the scores of the same patients using
AQL-5D, since the additional information captured by AQL-6D is
either neutral (no pain) or worse (moderate or extreme pain/
discomfort).
The COGENT study at the University of Newcastle was a before
and after, cluster randomised controlled trial, the objective of
which was to evaluate the use of computerised decision support
(CDS) systems in implementing clinical guidelines for the primary
care management of asthma in adults (Eccles et al., 2000). UK
practises which used their computer systems intensively were
eligible for the study. Asthma patients aged 18 and over who were
registered with the participating practises were identiﬁed from
a computerised search. Patient-reported outcome questionnaires,
including generic measures EQ-5D and SF-36, as well as asthma-
speciﬁc measures NASQ (the Newcastle Asthma Symptom Ques-
tionnaire, Eccles et al. 2000) and AQLQ were administered in 3
rounds approximately 1 year apart. The analysis reported here uses
round 1 data (n ¼ 3059) but includes only observations with no
missing data across all items required to produce an AQL-6D score
(n ¼ 2791). The AQL-6D is constructed from the AQLQ and EQ-5D.
Mean age of the sample is 48.07 years (s.d. ¼ 17.60) and 60.01%
are female. For further details of the study, see Eccles et al (2000).
Values generated by the AQL-5D and AQL-6D will be compared
in terms of mean scores for the whole sample and for sub-samples
grouped by asthma symptom scores and pain/discomfort level.
The valuation data
The response rate for all eligible respondents answering their
door at time of interview was 45.8%. Respondents were excluded
from the analyses for valuing all states as identical and less than
one; valuing theworst possible health state higher than every other
state; or valuing all states as worse than dead. This resulted in the
exclusion of just 2 respondents out of 184 successfully conducted
interviews.
The characteristics of the respondents were comparable to those
of South Yorkshire and the UK for age and gender, but tended to
have a higher proportion of retired individuals, a lower proportion
of employed individuals and a lower mean EQ-5D score (0.80 vs.
0.86) (Table 2). There were no signiﬁcant differences between the
samples who valued the AQL-5D and AQL-6D in terms of age,
gender, employment, education and health (Table 3).
There were 1455 TTO values elicited from 180 respondents with
727 and 728 for the AQL-5D and the AQL-6D health states respec-
tively. Descriptive statistics across the health states are presented in
Table 4. Three pairs of matched states were each valued between 60
and 62 times, the worst states (33333 and 333333) were valued 91
times each and the remaining states were valued between 29 and
31 times.
Across all health states TTO values range from0.98 to 1.0, with
34.3% and 29.5% of observations having a value of 1.0 for ALQ-5D
and AQL-6D respectively. Mean values for the 35 health states
ranged from 0.26 to 0.98 and are generally lower than median
values reﬂecting the negatively skewed distribution. Standard
Table 2
Respondent characteristics.
Sample
(n ¼ 182)
South Yorkshire a England a
Mean age (s.d.) 51.07 (17.39) NA NA
Age distribution
18e40 31.3% 41.2% 41.6%
41e65 42.9% 39.1% 39.1%
Over 65 25.8% 19.7% 19.3%
Female 60.4% 51.2% 51.3%
Married/Partner 73.1% NA NA
Main activity
Employed or self-employed 33.0% 56.1% 60.9%
Unemployed (or
seeking work)
8.7% 4.1% 3.4%
Long-term sick 6.0% 7.7% 5.3%
Full-time student 2.2% 7.5% 7.3%
Retired 32.4% 14.4% 13.5%
Own home outright
or with a mortgage
78.0% 64.0% 68.7%
Renting property 22.0% 36.0% 31.3%
Secondary school is highest
level of education
44.0% NA NA
EQ-5D score (s.d.) 0.80 (0.26) NA 0.86 (0.23)b
a Statistics for South Yorkshire Health Authority and for England in the Census
2001. Questions used in this study and the census are not identical. The census
includes persons aged 16 and above whereas this study only surveys persons aged
18 and above. Age distribution is here reported as the percentage of all adults aged
18 and over.
b Interviews conducted in theMeasurement and Valuation of Health (MVH) study
in 1993 (Gudex et al, 1994).
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deviations were quite high and ranged from 0.07 to 0.58 and are
comparable to those found in the original valuation of the AQL-5D.
Results
Comparison of health state values
Across the 4 matched states, mean values for the best (0.97 vs.
0.98) and worst states (0.26 vs. 0.30) of AQL-5D and AQL-6D were
not found to be signiﬁcantly different (Table 4). The mean value of
12132 from the AQL-5D (0.70) was signiﬁcantly higher than 121323
from AQL-6D (0.56) (p-value¼ 0.061). By way of contrast, the mean
value for the AQL-5D state 23131 (0.64) was lower than the AQL-6D
state 231311 (0.78) (p-value ¼ 0.034).
Modelling of the preference data
There are four models presented in Table 5: OLS (models (1) and
(3)) and random effects models (models (2) and (4)) for the AQL-5D
and AQL-6D descriptive systems. The OLS and random effects
models are quite similar, so the remaining presentation focuses on
the latter.
For AQL-5D model (2) the coefﬁcients across the 5 dimensions
are consistent with the severity levels within each dimension i.e.
coefﬁcients for level 3 > level 2 > level 1. The only exception is the
sleep dimension, where the level 2 coefﬁcient has the ‘wrong’ sign
though it is very small and non-signiﬁcant. Level 3 of breath,
weather and sleep are signiﬁcant as are levels 2 and 3 for activities.
The RMSE at the individual level is quite high at 0.398, but the MAE
at the state level is only 0.038 and this compares very favourably
with that achieved in the original model of 0.047 (Yang et al, 2011).
The plot of observed and predicted mean health state TTO values
and residuals ordered by mean observed value suggests there is no
obvious pattern in the errors (Fig. 1). The N3 term was not signiﬁ-
cant in any model.
For AQL-6D the pain/discomfort dimension had signiﬁcant
coefﬁcients for levels 2 and 3 at the 5% level, with level 3 pain/
discomfort having the largest coefﬁcient (0.301) of any dimension
in the AQL-6D for model (4). There were 3 inconsistencies with
levels 2 of breath (0.001), weather (0.016), and sleep (0.001)
being negative, but these are all below 0.02 and none were
signiﬁcant. Overall the model performed well in terms of MAE
(0.030 vs. 0.038 for AQL-5D) at the state level and again there is no
obvious pattern in the errors. There was little change to the coef-
ﬁcients for concern and sleep compared to the AQL-5D model, but
a noticeable reduction in the coefﬁcient for level 3 of weather
(whichwas signiﬁcant in the AQL-5Dmodel at the 5% level but non-
signiﬁcant in the AQL-6D model). However, there were substantial
reductions in the coefﬁcients for shortness of breath and activities,
particularly for the level 3 coefﬁcients of 0.167 vs. 0.047 and 0.307
vs. 0.150 for the AQL-5D and AQL-6D models respectively. The
results of the z-tests conﬁrm that there were signiﬁcant differences
between the AQL-5D and AQL-6Dmodels in the coefﬁcients of level
3 for shortness of breath and activities at the 1% level.
The marginal results for the Tobit model are reported in Table 6.
They are entirely consistent for the AQL-5Dwith RE (model (6)) and
there is only one inconsistency, namely one very small negative
value (weather level 2) for AQL-6D in model (8). The Tobit models
performance is slightly lower than the other models in terms of
RMSE and MAE. The Tobit models, however, show the same key
results: the levels for the add-on pain/discomfort dimension have
signiﬁcant coefﬁcients; the coefﬁcients for pain/discomfort at level
3 are the largest across all dimensions; in comparison to the AQL-
5D models there are substantial and signiﬁcant reductions in the
level 3 coefﬁcients for shortness of breath and activities.
Table 3
Respondent characteristics for AQL-5D and AQL-6D.
AQL-5D
(n ¼ 91)
AQL-6D
(n ¼ 91)
P-
valuea
Mean age (s.d.) 52.13 (17.54) 50.01 (17.27) 0.412b
Age distribution
18e40 27.5% 35.2% 0.263
41e65 46.2% 39.6% 0.369
Over 65 26.4% 25.3% 0.866
Female 61.5% 59.3% 0.762
Married/partner 70.3% 75.8% 0.403
Main activity
Employed or self-employed 30.8% 35.2% 0.528
Unemployed (or seeking work) 11.0% 6.6% 0.295
Long-term sick 3.3% 8.8% 0.120
Full-time student 3.3% 1.1% 0.310c
Housework 9.9% 15.4% 0.265
Retired 36.3% 28.6% 0.268
Own home outright or with a mortgage 76.9% 79.1% 0.720
Renting property 23.1% 20.9%
Secondary school is highest level of
education
46.2% 41.8% 0.550
Doubtful whether respondent
understood TTO
(interviewer reported)
2.2% 1.1%
Have asthma 25.3% 23.1% 0.729
Have moderate pain or discomfort 39.6% 30.8% 0.214
Have extreme pain or discomfort 4.4% 8.8% 0.232
EQ-5D score (s.d.) 0.79 (0.25) 0.80 (0.28) 0.850b
Time taken 31.85 (8.24) 31.62 (8.89) 0.856b
a Pearson Chi-square p-value.
b ANOVA p-value.
c Fisher’s exact test p-value (2-sided) as the expected frequency is 5 or lower.
Table 4
Health state values for AQL-5D and AQL-6D.
Measure Health state n Mean (s.d.) Median IQR Min Max
AQL-5D 11111a 60 0.97 (0.14) 1.00 1.00e1.00 0.03 1.00
11231 31 0.75 (0.42) 0.93 0.70e1.00 0.98 1.00
11321 60 0.89 (0.18) 1.00 0.83e1.00 0.03 1.00
12123 29 0.69 (0.31) 0.78 0.44e0.97 0.30 1.00
12132b 62 0.70 (0.41) 0.78 0.64e1.00 0.98 1.00
13213 31 0.46 (0.58) 0.63 0.03e0.93 0.93 1.00
13312 62 0.64 (0.50) 0.80 0.50e1.00 0.98 1.00
21222 60 0.78 (0.33) 0.90 0.66e1.00 0.98 1.00
22311 30 0.86 (0.21) 0.93 0.79e1.00 0.13 1.00
23113 31 0.33 (0.56) 0.50 0.03e0.78 0.98 1.00
23131c 60 0.64 (0.44) 0.80 0.54e0.95 0.98 1.00
31112 29 0.89 (0.15) 0.95 0.83e1.00 0.40 1.00
31333 29 0.49 (0.37) 0.50 0.30e0.76 0.48 1.00
32211 31 0.79 (0.44) 1.00 0.78e1.00 0.98 1.00
33121 31 0.72 (0.33) 0.75 0.53e1.00 0.28 1.00
33333d 91 0.26 (0.53) 0.33 0.00e0.63 0.98 1.00
AQL-6D 111111a 61 0.98 (0.07) 1.00 1.00e1.00 0.50 1.00
112322 31 0.77 (0.21) 0.80 0.60e1.00 0.35 1.00
121323b 60 0.56 (0.40) 0.55 0.36e0.89 0.70 1.00
123212 30 0.84 (0.20) 0.93 0.78e1.00 0.28 1.00
132231 30 0.86 (0.23) 0.98 0.79e1.00 0.00 1.00
133133 31 0.40 (0.46) 0.50 0.00e0.83 0.88 1.00
211232 30 0.69 (0.23) 0.70 0.47e0.89 0.20 1.00
213333 30 0.44 (0.52) 0.50 0.25e0.91 0.93 1.00
222213 31 0.66 (0.32) 0.73 0.50e0.93 0.23 1.00
223121 30 0.90 (0.19) 1.00 0.90e1.00 0.13 1.00
231311c 61 0.78 (0.24) 0.90 0.54e1.00 0.10 1.00
232122 30 0.79 (0.20) 0.83 0.64e1.00 0.28 1.00
312113 30 0.65 (0.35) 0.73 0.49e0.94 0.48 1.00
313221 31 0.83 (0.17) 0.85 0.75e1.00 0.30 1.00
321132 30 0.78 (0.25) 0.85 0.53e1.00 0.03 1.00
322331 30 0.68 (0.33) 0.74 0.48e0.93 0.48 1.00
331223 31 0.52 (0.44) 0.63 0.25e0.85 0.93 1.00
333312 30 0.73 (0.23) 0.76 0.56e0.93 0.23 1.00
333333d 91 0.30 (0.48) 0.33 0.00e0.65 0.98 1.00
Notes: Matched health states (those with 5 shared dimensions) across both studies
are in bold. Results of independent t-test comparing matched states: a. p ¼ 0.492, b.
p ¼ 0.061, c. 0.034, d. 0.576.
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Application to clinical trial data
Models (2) and (4) in Table 5 have been applied to the COGENT
trial data set using patient level completed AQLQ and EQ-5D data
(Table 7). AQL-5D is derived from the AQLQ data and AQL-6D also
uses the pain/discomfort dimension of the EQ-5D. Mean health
state values produced using the AQL-5D are typically lower than
the values produced using the AQL-6D by 0.1. The AQL-5D value is
consistently lower than the AQL-6D value across the 5 asthma
symptom severity groups, with the most severe asthma group
having the largest difference.
To better understand the impact of the pain/discomfort
dimension, the data set was divided into those reporting extreme,
moderate and no pain using the EQ-5D pain/discomfort dimension.
Except for the extreme pain/discomfort group, mean AQL-5D scores
continue to be lower than mean AQL-6D scores, regardless of
asthma symptom severity. For those with extreme pain/discomfort,
AQL-5D scores are higher. Amongst this group, milder asthma
symptoms are associated with larger differences between the AQL-
5D and AQL-6D scores, but the 2 instruments result in very similar
values for those with very severe asthma symptoms and extreme
pain/discomfort. However, the numbers are low for some of the
groups since only 6% of the sample report extreme pain/discomfort.
The general pattern of AQL-6D exceeding AQL-5D is reﬂected in
Fig. 2, where the predictions are ordered by AQL-5D health state
value.
Discussion
The health economics literature has tended to focus on the
issues surrounding the valuation of health states, such as which
valuation technique and whose values, rather than the role of the
descriptive system. This study shows quite clearly that the content
of the health state classiﬁcation plays an enormous role in deter-
mining the values that are generated. The addition of the pain/
discomfort dimension generated not only signiﬁcant coefﬁcients in
its own right, but also had a signiﬁcant impact on the coefﬁcients of
other dimensions. The adding-on of pain/discomfort was not
simply additive in its impact on health state values.
Some degree of preference interaction has been shown to exist
in a number of generic preference-based measures. For the HUI2
and HUI3 measures, a constant ‘k’ term was included in a multi-
plicative function that is consistent with preference complemen-
tarity (Feeny, Furlong, Torrance, & et al, 2002). For exposition
purposes, imagine a set of health states where all other dimensions
are at the best level, then preference complementarity is where the
sum of the disutility associated with being in the bottom level of
one dimension (say pain) and the disutility with being at the
bottom of another dimension (say mobility) is less than the
disutility associated with being at the bottom of these two
dimensions together (Feeny, 2002). Evidence against a simple
linear addition of main effects was also found in the signiﬁcance of
the additive ‘N3’ term for the EQ-5D and ‘MOST’ term for the SF-6D,
which provided extra disutility where one of the dimensions was at
its worse level, though these are not interaction terms in them-
selves (Brazier et al., 2002; Dolan, 1997). However, our study shows
that the impact of the additional dimension for pain/discomfort is
not consistent across dimensions and that a simple additive
adjustment such as the N3 component of the UK EQ-5D value set or
a constant multiplicative term as used for the Canadian valuation of
the HUI2 and HUI3 would not adequately capture the effect of
Table 5
Regression analysis estimating values sets for AQL-5D and AQL-6D.
AQL-5D AQL-6D Z-score
(1) (2) (3) (4) (1) v (3) (2) v (4)
Concern2 0.039 0.032 0.031 0.034 0.170 0.052
Concern3 0.035 0.041 0.046 0.047** 0.210 0.165
Breath2 0.042 0.019 0.011 0.001 0.984 0.502
Breath3 0.200*** 0.167*** 0.054* 0.047* 2.853*** 3.177
Weather2 0.069 0.024 0.015 0.016 1.599 1.035
Weather3 0.058 0.057** 0.034 0.033 0.513 0.734
Sleep2 0.001 0.016 0.017 0.001 0.346 0.471
Sleep3 0.121*** 0.106*** 0.099*** 0.091*** 0.471 0.431
Activities2 0.080** 0.074*** 0.042 0.040* 0.795 0.978
Activities3 0.290* 0.307*** 0.137*** 0.150*** 2.921*** 4.213***
Pain2 0.071** 0.071***
Pain3 0.303*** 0.301***
Constant 0.034 0.061 0.019 0.023 0.260 0.681
Observations 727 727 728 728
Number of id 91 91
R-squared 0.223 0.280
Root MSE 0.398 0.398 0.323 0.323
MAE (state level) 0.031 0.038 0.027 0.030
Notes: * signiﬁcant at 10%; ** signiﬁcant at 5%; *** signiﬁcant at 1%.
Fig. 1. Observed and predicted values for AQL-5D model (2).
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adding pain/discomfort. This has important implications for the use
of measures, condition-speciﬁc or generic, that exclude important
dimensions.
Another important result has been the way that adding a pain/
discomfort dimension to the descriptive system has increased the
value of the health state of most asthma patients in the COGENT
trial except for those 6% with extreme pain/discomfort. This is also
reﬂected in the results for the matched pairs where adding pain/
discomfort at level 3 to 12132 reduces the values, as might be
expected, but adding pain/discomfort at level 1e23131 has signif-
icantly increased the health state value. There was a similar ﬁnding
in a study adding an additional sleep dimension to EQ-5D, where
adding sleep level 1 to one of the two states signiﬁcantly increased
the mean health state value (0.179e0.486), though it did not alter
the value of any other matched EQ-5D states (Yang et al, 2008).
AQL-6D values even exceed those for AQL-5D in those with level 2
pain/discomfort in the COGENT study.
These apparently paradoxical results can be explained in
a number of different ways. At least some respondents valuing the
AQL-5D state may assume that the state being valued may involve
pain/discomfort compared to respondents valuing the AQL-6D
being told the state does not involve pain/discomfort. The ambi-
guity lies in the word discomfort and what has been read into this
word by respondents. This may explain why AQL-5D scores are
lower than AQL-6D scores for corresponding states with no pain/
discomfort. In order to explain why AQL-5D scores are still lower
than AQL-6D scores withmoderate pain/discomfort, themagnitude
of the unmentioned but imagined pain/discomfort needs to be
quite substantial. Another explanation is that respondents may
focus on one dominant dimension as part of a heuristic to simplify
the task. For AQL-5D this is breathlessness or activities and for AQL-
6D this for manymay become pain/discomfort. This is related to the
focussing effect mentioned earlier where respondents exaggerate
the importance of asthma related problems, but the addition of the
pain/discomfort dimension with no problems helps put those
asthma problems into perspective and so they become less
important (as reﬂected in the lower weights). Finally, there may be
a simple explanation based on a simple heuristic, such as counting
the number of level 1s and so adding level 1 pain/discomfort
makes the state look better. Addressing these types of questions
is better probed using more in-depth methods, such as cognitive
de-brieﬁng. Whatever the explanation, these all raise serious
concerns about missing dimensions from any health state
descriptive system.
There are a number of weaknesses to take into account with this
study. Firstly, it was only possible to design a study to estimate
additive functional forms similar to those that already exist for the
EQ-5D. It would have been desirable to have estimated more
Table 6
Tobit regression analysis estimating values sets for AQL-5D and AQL-6D.
AQL-5D AQL-6D Z-score
(5) Marginal
effects
(6) Marginal
effects
(7) Marginal
effects
(8) Marginal
effects
(5) V (7) (6) V (8)
Concern2 0.042 0.039 0.039* 0.035* 0.031 0.029 0.031 0.029 0.270 0.260
Concern3 0.042 0.039 0.045** 0.042** 0.046* 0.044* 0.045** 0.042** 0.102 0.015
Breath2 0.035 0.032 0.021 0.020 0.006 0.006 0.003 0.003 0.940 0.578
Breath3 0.163*** 0.150*** 0.143*** 0.131*** 0.057** 0.054** 0.049** 0.046** 2.552** 2.961***
Weather2 0.045 0.041 0.016 0.015 0.010 0.009 0.007 0.007 1.274 0.740
Weather3 0.050* 0.046* 0.049** 0.045** 0.029 0.027 0.027 0.026 0.538 0.783
Sleep2 0.018 0.017 0.028 0.025 0.019 0.018 0.002 0.002 0.032 0.820
Sleep3 0.117*** 0.108*** 0.106*** 0.097*** 0.091*** 0.086*** 0.080*** 0.075*** 0.676 0.908
Activities2 0.069** 0.064** 0.066*** 0.060*** 0.035 0.033 0.035* 0.033* 0.858 1.086
Activities3 0.264*** 0.236*** 0.274*** 0.244*** 0.124*** 0.116*** 0.140*** 0.130*** 3.284*** 4.282***
Pain2 0.073** 0.069** 0.068*** 0.063***
Pain3 0.280*** 0.260*** 0.275*** 0.254***
Constant 0.032 0.056 0.023 0.035 0.204 0.444
Observations 727 728 727 729
Number of id 91 92
Pseudo R-
squared
0.322 0.418
Root MSE 0.404 0.404 0.326 0.326
MAE (state
level)
0.059 0.062 0.041 0.042
Notes: * signiﬁcant at 10%; ** signiﬁcant at 5%; *** signiﬁcant at 1%.
Table 7
Application of AQL-5D and AQL-6D to a patient data set (n ¼ 2791).
All patients No pain/discomfort in EQ-5D Moderate pain/discomfort in
EQ-5D
Extreme pain/discomfort in
EQ-5D
AQL-5D AQL-6D AQL-5D AQL-6D AQL-5D AQL-6D AQL-5D AQL-6D
Mean (s.d.) Mean (s.d.) n Mean (s.d.) Mean (s.d.) n Mean (s.d.) Mean (s.d.) n Mean (s.d.) Mean (s.d.) n
All patients 0.733 (0.188) 0.833 (0.144) 2791 0.817 (0.119) 0.930 (0.060) 1245 0.677 (0.198) 0.787 (0.108) 1373 0.563 (0.226) 0.495 (0.126) 173
Asthma symptoms score
0 < NASSa20 (least severe) 0.884 (0.087) 0.933 (0.069) 625 0.892 (0.089) 0.962 (0.040) 446 0.864 (0.083) 0.878 (0.035) 164 0.871 (0.071) 0.649 (0.025) 15
20 < NASS40 0.808 (0.083) 0.893 (0.072) 528 0.817 (0.078) 0.933 (0.043) 302 0.795 (0.088) 0.853 (0.045) 214 0.803 (0.065) 0.621 (0.041) 12
40 < NASS60 0.759 (0.114) 0.859 (0.090) 583 0.781 (0.093) 0.915 (0.052) 267 0.742 (0.128) 0.828 (0.065) 295 0.721 (0.137) 0.589 (0.078) 21
60 < NASS80 0.697 (0.149) 0.805 (0.122) 478 0.743 (0.122) 0.897 (0.067) 155 0.680 (0.156) 0.791 (0.086) 285 0.637 (0.155) 0.538 (0.087) 38
80 < NASS100 (most severe) 0.489 (0.189) 0.655 (0.157) 539 0.624 (0.155) 0.831 (0.091) 64 0.486 (0.187) 0.681 (0.106) 389 0.401 (0.163) 0.407 (0.099) 86
Notes: a. NASS is the Newcastle Asthma Symptoms Score.
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complex functional forms such as multiplicative or multi-linear
functional (Keeney and Raiffa, 1993). This was a consequence of
funding limitations, but it was adequate for answering the primary
question of whether adding a dimension to a descriptive system
impacted on the size of the coefﬁcients associated with other
dimensions (including signiﬁcant changes), though probably not
for generating results for a new extended CSPBM. Secondly, the
MVH TTO protocol can be criticised for using a 10 year time frame
that is unrealistic in younger populations. It was selected due the
evidence on its reliability in the general population and given this is
a methodological study, it should not have any major implications
for the ﬁndings of the study. Thirdly, the subject of the study has
been one condition-speciﬁc instrument and this may limit the
generalisability of the results to other CSPBMs or perhaps more
importantly for policy makers, to generic preference-based
measures. The results will be speciﬁc to asthma and the addition
of pain/discomfort in particular, but CSPBMs by deﬁnition tend to
exclude many common and important domains and so the general
issue addressed by this study is relevant. Even generic measures
exclude potentially important dimensions such as cognition and
energy in the EQ-5D. However, whether other dimensions would
have such a strong impact as pain/discomfort remains to be seen.
This study has found that adding a common and generic
dimension to a CSPBM has an impact on the decrements associated
with the dimensions speciﬁc to the condition. Comparability
between measures (condition-speciﬁc or generic), requires among
other things that the impact of different dimensions on preferences
is additive, whether or not they are included in the classiﬁcation
system. Our results cast doubt on this assumption for important
dimensions like pain/discomfort.
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